Latest Cancer treatments Stories
- New, long-term preliminary data from Phase II STAND trial to be presented at 2015 Genitourinary Cancers Symposium (ASCO GU) LAVAL, Quebec, Feb.
The Hong Kong Polytechnic University (PolyU) entered into a license agreement on 13 February 2015 with a global oncology specialist company, Kinex Pharmaceuticals, Inc.
A Follow-On Combination Trial in First-Line Ovarian Cancer in the Neo-Adjuvant Setting Has Been Accepted by FDA LAWRENCEVILLE, N.J., Feb.
NEW YORK, Feb. 19, 2015 /PRNewswire/ -- Novogen presented yesterday (Wednesday February 18) to an audience of stockholders, analysts, investors and investment bankers.
DUBLIN, Feb .11, 2015 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/ptgkrh/drug_delivery_in)
The U.S. healthcare system is about to be deluged with diagnoses of early-stage lung cancers. SAN RAFAEL, Calif., Feb.
Selective RORgamma agonist product candidates demonstrated activity as single agent therapy NEW YORK and ANN ARBOR, Mich., Feb.
Nation’s largest cancer magazine reports on beloved television host’s experiences, guidance for others. Plainsboro, NJ (PRWEB) February 05, 2015
LUGANO, Switzerland and COPENHAGEN, Denmark, February 5, 2015 /PRNewswire/ -- - Elsiglutide is a GLP-2 receptor agonist with potential as a first-ever therapy to help cancer
New guidebook helps patients, doctors come together to make most of available treatment options. MADISON, Wisc.
- The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
- A sleeping-potion; a soporific.
- To mutter deliriously.
More Images (3 images) »